Eurepa V 5 contains Repaglinide. Eurepa V 5 uses:
Eurepa V 5 is indicated as an adjunct to diet and exercise to lower the blood glucose level in patients with type 2 diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled satisfactorily by diet and exercise alone. It is also indicated for use in combination with Metformin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by exercise, diet, and either Eurepa V 5 or Metformin alone. Eurepa V 5 binds to specific receptors in the cell membrane leading to the closure of ATP dependent K+ channels and the depolarisation of cell membrane. This in turn, leads to Ca++ influx, increased intracellular Ca++ and the stimulation of insulin secretion.
|Brand Name:||Eurepa V 5|
|Therapeutic Class:||Meglitinide Analogues|
|Manufacturer:||TORRENT PHARMACEUTICALS LTD|
|Last Updated:||2020-11-20 18:15:00|
Eurepa V 5 contains Repaglinide 0.5 Mg. Eurepa V 5 doses
Eurepa V 5 has to be taken just before or up to 30 minutes before the meal. Eurepa V 5 can be taken two, three or four times a day, depending on how many meals are taken. If a meal is missed, Eurepa V 5 should also be avoided. If an extra meal is taken, an extra dose of Eurepa V 5 should be taken with that meal. If a dose of Eurepa V 5 is missed, it should not be taken between meals.
Rather the usual dose should be taken before the next meal. The dose ranges from 0.5 to 4 mg before each meal. The starting dose of Eurepa V 5 in patients with HbA1c <8% is 0.5 mg before each meal. In patients with HbA1c >8% the starting dose is 1 or 2 mg before each meal. The dose may be increased gradually up to 4 mg before each meal.
Hypoglycaemia is possible with all blood glucose lowering drugs. If there are symptoms of low blood glucose (for example, headache, dizziness, tiredness, nervousness or shakiness, rapid heartbeat, or nausea), blood glucose should be tested right away. If it is low (less than 70 mg/dl on a home glucose meter), a simple carbohydrate food (for example, orange juice, quick dissolving sugar, candies, or glucose tablets) should be taken. If the symptoms do not go away, doctor should be informed. Some of the other common symptoms reported by patients taking Eurepa V 5 include cold and flu-like symptoms, diarrhoea, joint ache, and back pain. There is some evidence that oral anti-diabetic drugs may increase the risk of heart problems. But experts are not sure what the real risk is, if any, from taking oral anti-diabetic drugs.
Eurepa V 5 stimulates release of insulin from pancreatic β-cells by inhibiting K efflux via closure of ATP regulated K channels. This results in depolarization of the cell and opening of voltage-dependent Ca channels, which increases influx of Ca into the beta cells and causes release of insulin.
Eurepa V 5 should also be used with caution in renal and hepatic insufficiency.
The dose of Eurepa V 5 may need to be adjusted, if taken with other medications. The possible interactions of Eurepa V 5 with other drugs are:
In pregnancy, safety of Eurepa V 5 has not been established. Hence, Eurepa V 5 should be used during pregnancy only if it is clearly needed. It is not known whether Eurepa V 5 is excreted in human milk. Because many drugs are excreted in human milk and because of potential for serious adverse reactions in nursing infants from Eurepa V 5, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
Eurepa V 5 is contraindicated in patients with diabetic ketoacidosis, with or without coma, in patients with type I diabetes and in patients with known hypersensitivity to any of the components of the product.
Patients receiving up to 80 mg of Eurepa V 5 developed few adverse effects other than lowering of blood glucose. Hypoglycemia did not occur when meals were given with these high doses. Severe hypoglycemic reactions with coma, seizure or other neurological impairment occur infrequently.
Store below 25° C. Protect from moisture.
Eurepa V 5 Tablet price in India 108.8